High dose vitamin D exacerbates central nervous system autoimmunity by raising T-cell excitatory calcium.
暂无分享,去创建一个
W. Brück | S. Zamvil | T. Bertsch | M. Djukic | R. Nau | C. Larochelle | Martin S. Weber | Sebastian Torke | Darius Häusler | E. Peelen
[1] Jorge R. Oksenberg,et al. The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. , 2017, Trends in genetics : TIG.
[2] T. Jin,et al. 1,25‐dihydroxyvitamin D3‐induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells , 2017, Immunology.
[3] S. Feske,et al. Store‐Operated Ca2+ Entry Controls Clonal Expansion of T Cells through Metabolic Reprogramming , 2017, Immunity.
[4] P. Bhargava,et al. Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. , 2017, JCI insight.
[5] F. Barkhof,et al. High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis (RRMS) receiving subcutaneous interferon β-1a (scIFNβ-1a) (S44.005) , 2017 .
[6] J. Hell,et al. Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis , 2017, Proceedings of the National Academy of Sciences.
[7] D. Hougaard,et al. Neonatal vitamin D status and risk of multiple sclerosis , 2017, Neurology.
[8] J. Damoiseaux,et al. Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study , 2016, Journal of Neuroimmunology.
[9] H. Bading,et al. Nuclear calcium is required for human T cell activation , 2016, The Journal of cell biology.
[10] C. Lawes,et al. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. , 2016, The American journal of clinical nutrition.
[11] A. Hanff,et al. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men , 2016 .
[12] W. Brück,et al. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen , 2016, Acta Neuropathologica.
[13] P. Bhargava,et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis , 2016, Neurology.
[14] H. Søndergaard,et al. Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis , 2015, Multiple sclerosis.
[15] M. Behmanesh,et al. Vitamin D supplementation up-regulates IL-6 and IL-17A gene expression in multiple sclerosis patients. , 2015, International immunopharmacology.
[16] C. Greenwood,et al. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study , 2015, PLoS medicine.
[17] T. Yednock,et al. Melanoma cell adhesion molecule–positive CD8 T lymphocytes mediate central nervous system inflammation , 2015, Annals of neurology.
[18] S. Nessler,et al. Vitamin D deficiency decreases survival of bacterial meningoencephalitis in mice , 2015, Journal of Neuroinflammation.
[19] J. Wetterslev,et al. Vitamin D supplementation for prevention of mortality in adults. , 2014, The Cochrane database of systematic reviews.
[20] A. Damasceno,et al. Unfavorable outcomes during treatment of multiple sclerosis with high doses of vitamin D , 2014, Journal of the Neurological Sciences.
[21] P. Bhargava,et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. , 2014, Contemporary clinical trials.
[22] E. Granieri,et al. Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study , 2014, Multiple sclerosis.
[23] Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) , 2013, Inflammation Research.
[24] G. Cutter,et al. Disability in multiple sclerosis , 2013, Neurology.
[25] T. Sparwasser,et al. 1,25-dihydroxyvitamin D exerts similar immunosuppressive effects as UVR but is dispensable for local UVR-induced immunosuppression. , 2012, The Journal of investigative dermatology.
[26] C. Mathieu,et al. 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. , 2012, Immunobiology.
[27] T. Yednock,et al. Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. , 2012, Brain : a journal of neurology.
[28] A. Ponsonby,et al. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS , 2012, Neurology.
[29] T. Holmøy,et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment , 2012, Neurology.
[30] W. Hop,et al. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis , 2012, Neurology.
[31] M. Filippi,et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[32] F. Paul,et al. Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial , 2012, Trials.
[33] D. Goodin,et al. Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution. , 2012, Archives of neurology.
[34] D. Wingerchuk. Smoking: effects on multiple sclerosis susceptibility and disease progression , 2012, Therapeutic advances in neurological disorders.
[35] B. Baaten,et al. Regulation of Antigen-Experienced T Cells: Lessons from the Quintessential Memory Marker CD44 , 2011, Front. Immun..
[36] M. Stein,et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis , 2011, Neurology.
[37] H. Rieger,et al. Calcium microdomains at the immunological synapse: how ORAI channels, mitochondria and calcium pumps generate local calcium signals for efficient T‐cell activation , 2011, The EMBO journal.
[38] J. Damoiseaux,et al. Effects of vitamin D on the peripheral adaptive immune system: a review. , 2011, Autoimmunity reviews.
[39] C. Mayne,et al. 1,25‐Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis , 2011, European journal of immunology.
[40] P. Menheere,et al. Safety and T Cell Modulating Effects of High Dose Vitamin D3 Supplementation in Multiple Sclerosis , 2010, PloS one.
[41] S. Feske,et al. T‐cell‐specific deletion of STIM1 and STIM2 protects mice from EAE by impairing the effector functions of Th1 and Th17 cells , 2010, European journal of immunology.
[42] J. M. Burton,et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis , 2010, Neurology.
[43] A. Ascherio,et al. Vitamin D and multiple sclerosis , 2010, The Lancet Neurology.
[44] A. Ascherio,et al. Epstein–Barr Virus Infection and Multiple Sclerosis: A Review , 2010, Journal of Neuroimmune Pharmacology.
[45] H. DeLuca,et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin , 2009, Proceedings of the National Academy of Sciences.
[46] M. Holick,et al. Vitamin D status: measurement, interpretation, and clinical application. , 2009, Annals of epidemiology.
[47] J. Kinet,et al. Calcium signaling in immune cells , 2008, Nature Immunology.
[48] A. Kessels,et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis , 2008, Multiple sclerosis.
[49] C. Carlberg,et al. The vitamin D receptor. , 2007, Dermatologic clinics.
[50] S. Feske. Calcium signalling in lymphocyte activation and disease , 2007, Nature Reviews Immunology.
[51] P. Lipsky,et al. Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation , 2007, The Journal of Immunology.
[52] Y. Gwack,et al. Signalling to transcription: store-operated Ca2+ entry and NFAT activation in lymphocytes. , 2007, Cell calcium.
[53] M. Holick. Vitamin D deficiency. , 2007, The New England journal of medicine.
[54] A. Ascherio,et al. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors , 2007, Annals of neurology.
[55] A. Ascherio,et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.
[56] P. Duquette,et al. Statins reduce human blood–brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis , 2006, Annals of neurology.
[57] K. Spach,et al. Vitamin D3 Confers Protection from Autoimmune Encephalomyelitis Only in Female Mice1 , 2005, The Journal of Immunology.
[58] G. Rice,et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[59] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[60] Yan Zhu,et al. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. , 2004, The American journal of clinical nutrition.
[61] M. Holick. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. , 2004, The American journal of clinical nutrition.
[62] S. Khoury,et al. Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis , 2003, The Journal of experimental medicine.
[63] T. Meehan,et al. The vitamin D receptor is necessary for 1α,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice ☆ , 2002 .
[64] David F. Richards,et al. In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines , 2002, The Journal of experimental medicine.
[65] Richard S Lewis,et al. Calcium signaling mechanisms in T lymphocytes. , 2001, Annual review of immunology.
[66] H. DeLuca,et al. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. , 2000, Archives of biochemistry and biophysics.
[67] F. Nashold,et al. 1,25-Dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.
[68] R. Vieth,et al. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. , 1999, The American journal of clinical nutrition.
[69] Keli Xu,et al. Calcium oscillations increase the efficiency and specificity of gene expression , 1998, Nature.
[70] T. Jansen,et al. Severe hypercalcaemia syndrome with daily low-dose vitamin D supplementation. , 1997, British journal of rheumatology.
[71] H. DeLuca,et al. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[72] J. Herbert,et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis , 1994, Neurology.
[73] K. Miyazono,et al. A role of the latent TGF‐beta 1‐binding protein in the assembly and secretion of TGF‐beta 1. , 1991, The EMBO journal.
[74] J. Lemire,et al. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. , 1991, The Journal of clinical investigation.
[75] M. Holick. Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables. , 1987, Federation proceedings.
[76] M. Kuno,et al. Ion channels activated by inositol 1,4,5-trisphosphate in plasma membrane of human T-lymphocytes , 1987, Nature.
[77] S. Manolagas,et al. 1 alpha,25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. , 1986, Journal of immunology.
[78] S. Manolagas,et al. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.
[79] E. Acheson,et al. SOME COMMENTS ON THE RELATIONSHIP OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS TO LATITUDE, SOLAR RADIATION, AND OTHER VARIABLES , 1960, Acta psychiatrica Scandinavica. Supplementum.